145455-23-8
145455-23-8 結(jié)構(gòu)式
基本信息
L 692429
L-692,429 , CID121879
3-amino-3-methyl-N-[(3R)-2-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-4,5-dihydro-3H-1-benzazepin-3-yl]butanamide
物理化學(xué)性質(zhì)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/02/08 | HY-10957 | L-692429 | 145455-23-8 | 1 mg | 2181元 |
| 2025/02/08 | HY-10957 | L-692,429 , CID121879 L-692429 | 145455-23-8 | 5mg | 4800元 |
| 2025/02/08 | HY-10957 | L-692,429 , CID121879 L-692429 | 145455-23-8 | 10mM * 1mLin DMSO | 5381元 |
常見問題列表
Growth hormone secretagogue (GHS)
L-692429 stimulates intracellular calcium release, inositol phosphate (IP) turnover, cAMP-responsive element binding protein (CREB) activity, serum-responsive element activity and bioluminescence resonance energy transfer (BRET) activity with EC
50
values of 26 nM, 47 nM, 60 nM, 63 nM and 58 nM, respectively.
HeLa-T4 cells transiently expressing the flag epitope-tagged growth hormone secretagogue (GHS) receptor are treated with L-692429. The release of intracellular calcium is measured using fluorometry with the calcium indicator dye fluo-3/AM. Untransfected HeLa-T4 cells are unresponsive to L-692429 treatment, whereas HeLa-T4 cells transiently expressing GHS receptors demonstrate an increase in fluorescent emission after L-692429 treatment. A significant increase in luciferase activity after L-692429 treatment is seen, suggesting that activation of the GHS receptor stimulates the MAPK pathway.
When tested in anesthetized rats (Wistar rats), L-756867 inhibits L-692429 (100 μg/kg)-stimulated GH secretion in a dose-dependent manner. Complete inhibition is observed at an i.v. dose of 100 μg/kg of L-756867.